14 2025.02

ASCO GU｜RemeGen Announced Highly Encouraging Data from the Phase II Clinical Trial Evaluating Disitamab Vedotin plus Immunotherapy as Perioperative Regimen for Bladder Cancer

17 2025.01

JPM 2025 | RemeGen: Maximize Commercial Potential of Pipelines Through Indication Expansion and Therapy Innovation

07 2025.01

Published in Annals of Oncology: Disitamab Vedotin Combined with PD-1 Inhibitor is a Promising Treatment Option for Locally Advanced or Metastatic Urothelial Carcinoma

13 2024.12

2024 SABCS｜Results Unveiled for the Phase III Study of Disitamab Vedotin in Treating HER2-Positive Advanced Breast Cancer with Liver Metastasis

10 2024.11

"Dual Target": Telitacicept Offers New Hopes for Patients with B-Cell-Mediated Autoimmune Disorders

27 2024.10

Priority Review Granted to BLA of RemeGen’s Telitacicept for Its Third Indication of Myasthenia Gravis

17 2024.10

IGCS 2024 | Results of Disitamab Vedotin Combined with Cadonilimab for Cervical Cancer First Announced with ORR up to 50%

15 2024.10

BLA Accepted and Priority Review Granted to Disitamab Vedotin for Its Third Indication of HER2-Positive Advanced Breast Cancer with Liver Metastasis

27 2024.09

2024 CSCO｜Disitamab Vedotin Combined with Camrelizumab and S-1 as Perioperative Therapy for Gastric Cancer Showed Promising Efficacy with a pCR Rate of 30%

15 2024.09

2024 ESMO | Disitamab Vedotin Achieves 33 Months OS as First-Line Treatment of Advanced Urothelial Carcinoma